Ritonavir Revisited: Melt Crystallization Can Easily Find the Late-Appearing Polymorph II and Unexpectedly Discover a New Polymorph III
Molecular Pharmaceutics · 07.08.2023 · 20 (8) · 3854-3863
DOI: 10.1021/acs.molpharmaceut.2c00994 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 14.07.2023. Verfasst von Shuting Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China. Hauptthemen laut MEDLINE: Ritonavir, Polyethylene Glycols. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
ORCID-Profile: Ziqiao Chen, Ming Lu
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Li, S., Liu, B., Chen, Z., Ou, X., Rong, H., & Lu, M. (2023). Ritonavir Revisited: Melt Crystallization Can Easily Find the Late-Appearing Polymorph II and Unexpectedly Discover a New Polymorph III. Molecular Pharmaceutics, 20(8), 3854-3863. https://doi.org/10.1021/acs.molpharmaceut.2c00994
Vancouver
Li S, Liu B, Chen Z, Ou X, Rong H, Lu M. Ritonavir Revisited: Melt Crystallization Can Easily Find the Late-Appearing Polymorph II and Unexpectedly Discover a New Polymorph III. Molecular Pharmaceutics. 2023;20(8):3854-3863. doi:10.1021/acs.molpharmaceut.2c00994
BibTeX
@article{Li2023,
author = {Li, Shuting and Liu, Binbin and Chen, Ziqiao and Ou, Xiao and Rong, Haowei and Lu, Ming},
title = {Ritonavir Revisited: Melt Crystallization Can Easily Find the Late-Appearing Polymorph II and Unexpectedly Discover a New Polymorph III},
journal = {Molecular Pharmaceutics},
year = {2023},
volume = {20},
number = {8},
pages = {3854--3863},
doi = {10.1021/acs.molpharmaceut.2c00994}
}
EUVIMED